Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients

Rövid összefoglaló (regiszter, angolul)

The goal of this clinical trial is to find out if a medicine called Trelagliptin works as well as another medicine called Sitagliptin to lower blood sugar levels in people with type 2 diabetes who have not reached their target sugar levels with metformin alone. The main questions this study aims to answer are: Does Trelagliptin lower average blood sugar levels (measured by HbA1c) as well as Sitagliptin over 3 months? Does Trelagliptin help reduce swings in blood sugar levels compared to Sitagliptin? Are people more likely to stick to taking Trelagliptin, which is taken once a week, than Sitagliptin, which is taken every day? How satisfied are people with their treatment when using Trelagliptin versus Sitagliptin? Researchers will compare two groups: One group will take Trelagliptin once a week for 3 months. The other group will take Sitagliptin once a day for 3 months. Participants in the study will: Answer questions about their health and how they feel about their diabetes treatment. Have blood tests to measure blood sugar levels, including: HbA1c (an average measure of blood sugar over 2-3 months) Fasting blood sugar levels Blood sugar levels two hours after breakfast Keep records of how often they take their medicine. People can take part in this study if: They have type 2 diabetes and are taking metformin but still have higher-than-desired blood sugar levels. They are between certain blood sugar ranges (HbA1c higher than 6.5% but lower than 10%). They are willing to give informed consent and follow study instructions. People cannot take part if: They have type 1 diabetes. They have certain serious health conditions, such as severe kidney disease, heart problems, cancer, or are pregnant. They are already taking Trelagliptin or are in another clinical study. The study will take place at Khyber Teaching Hospital in Pakistan and will last about 3 months for each participant.

Mit vállalsz

• Vizsgálat típusa: Beavatkozással járó · 3. fázis
• Tervezett résztvevők: 126
• 2025. júl. 1. és az elsődleges befejezés (2026. dec. 26.) között
• 1 helyszín, 1 országban
• Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Kiket keres a vizsgálat

Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

Te vagy a koordinátor? Erősítsd meg az adatokat